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Incidence and Prognostic Significance of Depressive Symptoms
in Peripheral Artery Disease
Mary M. McDermott, MD; Jack M. Guralnik, MD, PhD; Lu Tian, ScD; Melina R. Kibbe, MD; Luigi Ferrucci, MD, PhD; Lihui Zhao, PhD; Kiang
Liu, PhD; Yihua Liao, MS; Ying Gao, MS; Michael H. Criqui, MD, MPH
Background-—We compared the incidence of depression, defined by a Geriatric Depression Score (GDS) ≥6, between people with
versus without peripheral artery disease (PAD). We determined whether depressive symptoms were associated with increased
mortality in people with and without PAD.
Methods and Results-—Nine hundred and fifty-one PAD patients and 478 non-PAD patients were recruited from Chicago medical
centers and followed prospectively. At baseline and annually, participants completed the GDS (0–15 scale, score ≥6=depression)
and 6-minute walk. Cause of death was confirmed with death certificates. The prevalence of a GDS ≥6 at baseline was 186/951
(19.6%) among PAD versus 63/478 (13.2%) among non-PAD participants (P=0.003). During a mean follow-up of 2.71.2 years,
122/712 (17.1%) of participants with PAD versus 51/403 (12.7%) without PAD developed a GDS ≥6 (P=0.047). Adjusting for age,
sex, race, comorbidities, and other confounders, PAD participants had an increased rate of developing a GDS ≥6 compared to non-
PAD participants (hazard ratio=1.54 (95% CI=1.05–2.25, P=0.026). This association was not statistically significant after adjusting
for 6-minute walk (P=0.258). Among PAD participants, a baseline GDS ≥6 was associated with increased all-cause mortality,
adjusting for confounders (hazard ratio=1.57, 95% CI=1.12–2.21, P=0.009). This association was not significant after adjusting for
6-minute walk (P=0.224).
Conclusions-—People with PAD have a higher incidence of depressive symptoms than people without PAD. In PAD, depressive
symptoms are associated with increased all-cause and cardiovascular mortality. These associations are explained in part by poorer
6-minute walk among people with PAD and among depressed people with PAD, respectively. ( J Am Heart Assoc. 2016;5:
e002959 doi: 10.1161/JAHA.115.002959)
Key Words: atherosclerosis • cardiovascular disease • peripheral vascular disease
T he incidence and prognostic significance of depressionin people with lower extremity peripheral artery disease
(PAD) are unclear. Cross-sectional studies report a higher
prevalence of depression or depressive symptoms among
people with PAD compared to those without PAD.1–3
However, to our knowledge, no prospective studies have
compared the incidence of depression or new depressive
symptoms among people with PAD compared to those
without PAD. Among patients with coronary artery disease,
individuals with depression have higher morbidity and mor-
tality rates than people without depression.4,5 One prior study
reported that among symptomatic patients undergoing lower
extremity revascularization, those with depression had a
higher risk of the combined outcome of death or major
adverse cardiovascular events than those without depres-
sion.6 However, the association of depression with mortality
among PAD patients, including those not planning revascu-
larization, has not been studied previously to our knowledge.
To determine whether patients with PAD have an
increased incidence of depressive symptoms compared to
people without PAD, we compared rates of new onset of
depressive symptoms over time between people with versus
without PAD. We hypothesized that people with PAD would
have a higher incidence of depressive symptoms compared
to people without PAD. To determine whether depressive
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symptoms are associated with increased all-cause and
cardiovascular disease (CVD) mortality in people with PAD,
we compared mortality rates between people with versus
without depressive symptoms. We hypothesized that among
people with PAD, those with depressive symptoms would
have a higher mortality rate than those without depressive
symptoms.
Methods
Study Overview
We combined data from 3 prospective observational studies
of patients with PAD: The Walking and Leg Circulation Study
(WALCS), WALCS II, and WALCS III cohorts.7–10 WALCS was
conducted between 1998 and 2002,7,8 WALCS II was
conducted between 2002 and 2006, and WALCS III between
2005 and 2014.9,10 In all 3 studies, PAD participants were
recruited from among consecutively identified PAD patients
at Chicago-area medical centers and followed longitudinally.
The institutional review boards of Northwestern University
and all participating medical centers approved the protocol
for the 3 studies. All participants gave written informed
consent. In each study, participants completed baseline
testing and returned annually for follow-up for up to 4 years.
In the WALCS cohort, all participants were age 55 and older
at baseline. In WALCS II, all participants were age 59 and
older at baseline. In WALCS III, there were no age
restrictions.
Participant Identification
Similar recruitment methods were used for all 3 studies.7–10
In all 3 cohorts, PAD participants were identified from among
consecutive patients with PAD in Chicago-area vascular
surgery and noninvasive vascular laboratories.7–10 Partici-
pants were also identified from among lists of consecutive
PAD patients in cardiology, general medicine, endocrinology,
and geriatric clinics at Northwestern. In the WALCS and
WALCS II cohorts, participants without PAD were identified
from among consecutive patients in a general internal
medicine practice who were screened with the ankle–brachial
index (ABI) and found to have an ABI of 0.90 to 1.50. In the
WALCS III cohort, participants without PAD were identified
(from among consecutive patients age 65 and older in
Northwestern’s general internal medicine practice) who had
no history of smoking, diabetes mellitus, or established
cardiovascular disease, including PAD. In addition, partici-
pants without PAD in WALCS I and WALCS II were identified
(from among consecutive patients in a noninvasive vascular
laboratory without PAD) who had an ABI of 0.90 to 1.50 at
their baseline study visit.
Inclusion Criterion
All PAD participants in these analyses had a baseline ABI
value of <0.90.11 All non-PAD participants included in these
analyses had a baseline ABI of 0.90 to 1.30.11
Exclusion Criteria
In all 3 studies, patients with dementia were excluded
because of their inability to answer questions accurately.
Nursing home residents were excluded because they had
severely impaired functioning at baseline. Non-English-speak-
ing patients were excluded because investigators were not
fluent in non-English languages. Patients with recent major
surgery were excluded because the surgery may have
influenced their walking speed, sitting down time, or lying
down time. Potential participants who were wheelchair bound
or who had a history of leg or foot amputations were excluded
because of their severe functional impairment at baseline. In
the WALCS III cohort, participants with contraindications to
magnetic resonance imaging testing were excluded. Partici-
pants with critical limb ischemia were not included in any
cohorts.
ABI Measurement
A hand-held Doppler probe (Nicolet Vascular Pocket Dop II;
Nicolet Biomedical Inc, Golden, CO) was used to measure
systolic pressures in the right and left brachial, dorsalis pedis,
and posterior tibial arteries.11,12 Each pressure was measured
twice. For each leg, the ABI was calculated by dividing the
mean of the dorsalis pedis and posterior tibial pressures by
the mean of the 4 brachial pressures.13 Average brachial
pressures in the arm with highest pressure were used when
one brachial pressure was higher than the opposite brachial
pressure in both measurement sets and the 2 brachial
pressures differed by 10 mm Hg or more in at least 1
measurement set. In these cases, subclavian stenosis was
possible.13 The leg with lowest ABI was used in analyses.
Depressive Symptoms
Depressive symptoms were measured at baseline and at
annual follow-up visits with the Geriatric Depression Scale
Short Form (GDS-S).14–17 The GDS-S is a well-validated 15-
item questionnaire, derived from the Center for Epidemiolog-
ical Studies Depression scale, which measures the number of
depressive symptoms. Scores range from 0 to 15 (15=worst
score).14–18 A GDS-S score ≥6 is 92% sensitive and 81%
specific for clinical depression, as defined by the Diagnostic
and Statistical Manual of Mental Disorders, Third Edition,
Revised (DSM-IIIR).14 “The GDS-S improves in response to a
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therapeutic intervention and changes in the GDS-S are
associated with temporally corresponding changes in the
ability to perform Activities of Daily Living and Instrumental
Activities of Daily Living.19,20”
Six-Minute Walk
The 6-minute walk test was performed at baseline using a
standardized and well-validated protocol.21,22 Participants
walked up and down a 100-foot hallway for 6 minutes after
instructions to cover as much distance as possible.
Comorbidities
Comorbidities assessed at baseline were diabetes, angina,
myocardial infarction, heart failure, cancer, chronic lung
disease, and stroke. Disease-specific algorithms that combine
data from patient report, medical record review, medications,
laboratory values, and a questionnaire completed by the
participant’s primary care physician were used to verify and
document baseline comorbidities.23
Medications
Participants were asked to bring their medication bottles or a
complete list of their medications to their baseline study visit.
Names of each medication were recorded. The study principal
investigator (M.M.M.) reviewed each medication, blinded to
other characteristics, and indicated whether the medication
was a statin, angiotensin-converting enzyme inhibitor, or
antiplatelet therapy.
Income
We used participants’ zip code linked to US census data to
categorize participants according to the median annual
household income in their zip code.24
Education Level
Participants were asked their highest level of education
achieved, using a questionnaire administered by trained and
certified interviewers.
Mortality Assessment
At baseline, participants provided names of 3 proxies to assist
with ascertaining complete follow-up. Mortality information
was obtained from family members, proxies, and primary care
physicians. For patients lost to follow-up, we used the Social
Security Administration death database to search for deaths.
Death certificates were obtained from the State of Illinois or
from medical records. Cardiovascular disease deaths con-
sisted of deaths due to coronary heart disease, stroke,
peripheral vascular disease, and other cardiovascular disease.
The date of death was obtained from the death certificate.
Follow-up for participants who were not deceased continued
until the date of last contact at a study visit or by telephone.
Statistical Analyses
Two-sample t tests and v2 tests were used to compare
continuous and binary baseline clinical characteristics,
respectively, according to the presence versus absence of
PAD and according to the presence versus absence of
depression at baseline. Two-sample t tests and v2 analyses
were also used to compare baseline characteristics of
participants without depression at baseline who developed
depression during follow-up versus those who did not develop
depression during follow-up among PAD and non-PAD
subgroups separately. We used Kaplan–Meier curves and
log-rank analyses to compare cumulative probabilities of
depression among participants with versus without PAD at
baseline. Among participants with and without PAD at
baseline, we used Kaplan–Meier curves and log-rank analyses
to compare cumulative probabilities of all-cause mortality
between participants with versus without depression at
baseline.
In our primary analyses, Cox regression models were used
to establish the association of PAD with development of
depression during follow-up, stratifying by study cohort
(WALCS I, WALCS II, or WALCS III), and adjusting for age,
sex, race, body mass index (BMI), smoking, comorbidities,
income, and education. In secondary analyses, we repeated
analyses with additional adjustment for baseline 6-minute
walk. We imputed income and/or education for 22 partici-
pants missing data on income or education, using the cohort
median for imputation.
Cox regression models were used to evaluate the associ-
ation of baseline characteristics with development of depres-
sion during follow-up among participants with and without
PAD, stratifying by study cohort, and adjusting for age, sex,
race, 6-minute walk, BMI, smoking, comorbidities, ABI,
income, and education.
In our primary analyses, Cox regression models were used
to establish the association of depression at baseline with all-
cause mortality and with cardiovascular disease mortality
among participants with and without PAD, respectively,
stratifying by study cohort, and adjusting for age, sex, race,
BMI, smoking, comorbidities, medications, income, education
level, and ABI. In secondary analyses, we repeated analyses
with additional adjustment for baseline 6-minute walk. We
tested for an interaction of study cohort with the associations
in our primary analyses.
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In post-hoc, exploratory analyses, we analyzed whether
greater decline in the 6-minute walk and whether greater
declines in the ABI were each associated with a higher
incidence of subsequent depression in participants with and
without PAD, respectively, using Cox proportional hazards
analyses. In these analyses we stratified participants with and
without PAD according to their degree of decline in the 6-
minute walk and their decline in the ABI during the first
2 years of follow-up and related each independent variable of
interest to the subsequent incidence of depression, adjusting
for confounders.
Analyses were performed using SAS statistical software
(version 9.4, SAS Institute Inc, Cary, NC).
Results
Among 1074 individual participants with PAD enrolled in the
WALCS I, WALCS II, and WALCS III cohorts, 29 were lost to
follow-up, 67 did not complete the GDS-S form at baseline,
and 27 were missing covariate data required for analyses
(Figure 1). Among 532 individual participants without PAD, 16
were lost to follow-up, 26 did not complete the GDS-S form at
baseline, and 12 were missing covariate data. The remaining
951 participants with PAD and 478 without PAD were
included in analyses.
Characteristics of Participants at Baseline
Overall, participants with PAD were older and had lower BMI
and ABI values compared to participants without PAD
(Table 1). Participants with PAD included a higher proportion
of men and had higher prevalences of current smoking,
diabetes, angina, heart failure, prior myocardial infarction, and
stroke, compared to people without PAD (Table 1). Partici-
pants with PAD had poorer 6-minute walk performance at
baseline and a lower baseline prevalence of spinal stenosis
compared to people without PAD. Participants with PAD had
higher prevalences of using statins, anti-platelet therapy, or
angiotensin-converting enzyme inhibitors than those without
PAD.
At baseline, 186/951 (19.6%) of participants with PAD met
criteria for depression versus 63/478 (13.2%) of those
without PAD (P=0.003). Table 1 shows characteristics asso-
ciated with presence versus absence of PAD and presence
versus absence of depression at baseline. Among participants
with PAD, those depressed at baseline were younger, included
a higher prevalence of current smokers, and included higher
prevalences of African Americans and people with pulmonary
disease, diabetes, history of stroke, heart failure, hip arthritis,
disk disease, and spinal stenosis (Table 1). PAD participants
with depression at baseline had poorer 6-minute walk
performance, a lower prevalence of cancer, achieved less
education, and lived in a zip code with lower median income
than PAD participants without depression at baseline
(Table 1). Participants without PAD who were depressed at
baseline had higher prevalences of current smoking, diabetes,
angina, and heart failure compared to participants without
PAD who were not depressed. Participants without PAD who
were depressed at baseline had poorer 6-minute walk
performance and had achieved lower levels of education than
those not depressed at baseline (Table 1).
Incidence of Depression During Follow-Up in
People With Versus Without PAD
Among all participants without depression at baseline, the
incidence of depression, measured by newly developing a
GDS ≥6 after baseline, was 122/712 (17.1%) among partic-
ipants with PAD and 51/403 (12.7%) among participants
without PAD during a mean follow-up of 2.71.2 years. The
cumulative probability of developing new depression during
follow-up between participants with versus without PAD at
baseline is shown in Figure 2 (log-rank test P=0.0026). There
was no association of PAD severity with incidence of
depression (ABI <0.50: 21/125 [16.8%], ABI 0.50 to <0.90:
101/587 [17.2%]; ABI 0.90–1.30: 51/403 [12.7%], P=0.139).
Among women, the incidence of depression was 53/279
(19.0%) among participants with PAD versus 29/221 (13.1%)
among those without PAD. Among men, the incidence of PAD
was 69/433 (15.9%) among those with PAD versus 22/182
(12.1%) among those without PAD. Among participants age
>75, the incidence of depression was 47/254 (18.5%) among
participants with PAD and 13/91 (14.3%) among participants
without PAD. Among participants age ≤75 years, the inci-
dence of depression was 75/458 (16.4%) among those with
PAD and 38/312 (12.2%) among those without PAD. There-
fore, the higher incidence of depression among people with
PAD compared to those without PAD was consistent among
men and women and in older and younger participants. There
was no interaction of study cohort with the analyses assessed
in our primary analyses (data not shown).
In analyses stratifying by study cohort, and adjusting for
age, sex, race, BMI, smoking, comorbidities, education, and
income, PAD was associated with a higher risk of develop-
ing new depression compared to people without PAD
(hazard ratio [HR]=1.54, 95% CI=1.05–2.25, P=0.026).
However, this association was no longer statistically signif-
icant when the analyses were additionally adjusted for
baseline 6-minute walk performance (HR=1.26, 95%
CI=0.85–1.86, P=0.258).
Among PAD participants, current smoking, heart failure,
knee arthritis, and 6-minute walk were each associated
independently with risk of developing depression during
follow-up (Table 2), in stratified analyses adjusting for age,
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sex race, BMI, comorbidities, ABI, income, and education
level. In a similar multivariable analysis among participants
without PAD, only 6-minute walk performance was associated
with developing depression during follow-up (Table 2).
PAD participants with depression at baseline had higher
all-cause mortality rates during follow-up compared to PAD
participants without depression at baseline (54/186 [29.0%]
versus 153/765 [20.0%]). The cumulative probability of all-
cause mortality between PAD participants with versus without
depression at baseline is shown in Figure 3A (log-rank test
P=0.005). In multivariable analyses, depression at baseline
was associated with higher all-cause mortality, stratifying by
study cohort, and adjusting for age, sex, race, comorbidities,
ABI, smoking, BMI, medication use, income, and education
level (HR=1.57, 95% CI=1.12–2.21, P=0.009) among people
with PAD (Table 3). However, this association was not
statistically significant after additional adjustment for 6-
minute walk (HR=1.25, 95% CI=0.87–1.79, P=0.224). In
multivariable analyses, depression at baseline was associated
with higher cardiovascular disease mortality, stratifying by
study cohort, and adjusting for age, sex, race, comorbidities,
ABI, smoking, BMI, medication use, income, and education
(HR=1.80, 95% CI=1.03–3.13, P=0.038) (Table 3) among
people with PAD. However, this association was not statis-
tically significant after additional adjustment for 6-minute
walk (HR=1.38, 95% CI=0.77–2.46, P=0.277) (Table 3).
WALCS Cohort
N=740
PAD: N=460
Non-PAD N=280
WALCS II Cohort
N=402
PAD: N=240
Non-PAD N=162
WALCS III Cohort
N=464
PAD: N=374
Non-PAD N=90
PAD N=1074 Non-PAD N=532
16 Lost to Follow-
up
WALCS: N=5
WALCS II: N=6
WALCS III N=5
N=516
26 Missing
Baseline
Depression Data
WALCS: N=14
WALCS 11: N=7
WALCS III: N=5
N=490
12 Missing One or
More Covariates
WALCS: N=0
WALCS 11: N=0
WALCS III: N=12
Non-PAD Cohort
N=478
Total Par cipants N=1429
N=1045
N=978
PAD Cohort
N=951
29 Lost to Follow-
up
WALCS: N=5
WALCS II: N=6
WALCS III N=18
67 Missing
Baseline
Depression Data
WALCS: N=36
WALCS 11: N=13
WALCS III: N=18
27 Missing One or
More Covariates
WALCS: N=0
WALCS 11: N=0
WALCS III: N=27
Figure 1. Summary of included participants from the Walking and Leg Circulation Study
(WALCS), WALCS II, and WALCS III cohorts. PAD indicates peripheral artery disease.
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PAD participants 712 711 562 93 8 1
Number of participants at risk
Non-PAD participants 403 403 345 262 155 87  8 1
315 172
Figure 2. Association of baseline peripheral artery disease status with new onset
of depressive symptoms among people without depressive symptoms at baseline.
Table 2. Multivariable Analyses of Baseline Characteristics Associated With Development of Depression During Follow-Up Among
Participants With and Without PAD
Participants With PAD (N=712) Participants Without PAD (N=403)
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Age, y 1.01 (0.98–1.03) 0.638 0.98 (0.94–1.02) 0.320
Male sex 0.87 (0.59–1.30) 0.502 1.10 (0.58–2.09) 0.777
African American race 0.66 (0.38–1.14) 0.136 0.56 (0.23–1.34) 0.190
Six-minute walk (feet) baseline (hazard ratio
calculated per 100 feet)
0.94 (0.89–1.00) 0.047 0.86 (0.79–0.93) <0.001
Body mass index, kg/m2 0.98 (0.95–1.02) 0.413 1.02 (0.97–1.07) 0.458
Current smoker 1.94 (1.21–3.12) 0.006 1.12 (0.26–4.82) 0.879
Diabetes 1.12 (0.74–1.71) 0.581 1.36 (0.62–2.96) 0.441
Pulmonary disease 1.05 (0.71–1.55) 0.817 1.29 (0.69–2.43) 0.426
Cancer 1.45 (0.91–2.31) 0.119 0.82 (0.33–2.07) 0.678
Angina 1.28 (0.82–1.98) 0.273 1.55 (0.66–3.66) 0.318
Myocardial infarction 1.05 (0.67–1.67) 0.822 1.14 (0.45–2.90) 0.782
Stroke 1.00 (0.58–1.72) 0.994 0.70 (0.16–3.11) 0.637
Heart failure 1.66 (1.04–2.66) 0.034 0.97 (0.41–2.30) 0.946
Hip arthritis 1.31 (0.44–3.91) 0.623 2.12 (0.54–8.39) 0.284
Knee arthritis 2.26 (1.35–3.77) 0.002 1.80 (0.79–4.14) 0.163
Disk disease 1.09 (0.72–1.65) 0.673 0.89 (0.48–1.68) 0.724
Spinal stenosis 1.46 (0.82–2.59) 0.194 1.42 (0.77–2.63) 0.258
Ankle brachial index 1.62 (0.42–6.24) 0.483 1.17 (0.06–24.31) 0.917
Median annual household income ≤$51 249 vs
median annual household income >$51 249
0.88 (0.59–1.31) 0.530 0.50 (0.26–0.99) 0.046
Less than high school vs graduate school 1.81 (0.90–3.65) 0.096 1.48 (0.49–4.53) 0.489
High school to college vs graduate school 1.17 (0.72–1.91) 0.535 0.86 (0.42–1.78) 0.691
PAD indicates peripheral artery disease.
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Among participants without PAD, there was no difference
in the cumulative probability of all-cause mortality among
those with versus without depression at baseline (Figure 3B).
Among participants without PAD, there was no difference in
all-cause or cardiovascular disease mortality among those
depressed at baseline compared to those not depressed at
baseline, stratifying by study cohort, and adjusting for age,
sex, race, comorbidities, ABI, smoking, BMI, education level,
income, and medications (HRs=1.32 [95% CI 0.57–3.06] and
0.85 [95% CI 0.14–5.12] respectively). There were no
significant interactions of presence versus absence of PAD
with the association of depression and all-cause or cardio-
vascular mortality (P=0.909 and 0.374, respectively).
Among participants with PAD, an ABI decline >0.15 or a
greater decline in the 6-minute walk during the first 2 years of
follow-up, respectively, were not associated with a higher
subsequent incidence of depression, adjusting for age, sex,
race, comorbidities, smoking, BMI, baseline ABI, baseline 6-
minute walk, income, or education (Tables 4 and 5, respec-
tively). Among participants without PAD, ABI declines >0.15
and greater declines in the 6-minute walk, respectively, were
associated with greater subsequent risk of depression,
adjusting for age, sex, race, comorbidities, smoking, BMI,
baseline ABI, baseline 6-minute walk, income, or education
(Tables 4 and 5, respectively).
Discussion
Among 951 participants with PAD and 478 without PAD, we
report new findings regarding the incidence and clinical
significance of depressive symptoms in people with PAD.
First, people with PAD had a higher prevalence of depression
at baseline and a higher rate of developing new depression
during follow-up compared to people without PAD. The
association of PAD with developing new depression was
independent of age, sex, race, smoking, BMI, comorbidities,
education, and income. However, the association of PAD with
increased risk of depressive symptoms was no longer
Number ofparticipants at risk
PAD participants without depression 765 750 695 639 579                    291                     68                     19
13PAD participants with depression 186 184 168 147                   131                     66 5
Number ofparticipants at risk
Non-PAD participants without depression 415 413 399 374 343                   181                     35                       6
Non-PAD participants with depression 63 61 56 50                      47                   35 13                       6
A
B
Figure 3. A, Association of depressive symptoms with all-cause mortality in partic-
ipants with peripheral artery disease (N=951); (B) Association of depressive symptoms
with all-cause mortality in participants without peripheral artery disease (N=478).
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statistically significant after additional adjustment for baseline
6-minute walk performance. Second, among people with PAD,
depression is an independent risk factor for all-cause
mortality, even after adjusting for age, sex, race, comorbidi-
ties, BMI, education, income, and smoking. However, this
association was no longer significant after adjusting for
baseline 6-minute walk performance.
PAD affects 8 million men and women in the United
States and nearly 200 million men and women world-
wide.25,26 PAD is associated with increased rates of all-cause
and cardiovascular disease mortality, compared to people
without PAD.26–28 PAD is also associated with greater
functional impairment and more rapid functional decline
compared to people without PAD.7,8,29,30 We found that 19.2%
of PAD participants and 12.9% of non-PAD participants met
criteria for depression at baseline in our cohort. In compar-
ison, the prevalence of depression using the Geriatric
Depression Scale, from which the GDS-S was derived, was
12% among 489 community-dwelling postmenopausal women
without PAD.31 Thus, the prevalence of GDS-S diagnosed
depression in our non-PAD cohort was comparable to the
prevalence of depression diagnosed with the full Geriatric
Depression Scale in a community-dwelling cohort. The
prevalence of GDS-S-diagnosed depression in our PAD cohort
was higher than the prevalence of depression diagnosed with
the full GDS in a community-dwelling cohort.31
Our findings are consistent with prior study in people
without PAD showing that depression is more common among
people with disability and that depression is associated with
disability and mobility loss.32–34 Similarly, PAD-related walk-
ing impairment may contribute to higher rates of new
depression among people with PAD compared to those
without PAD. Furthermore, the higher rate of all-cause
mortality in depressed people with PAD may be explained in
Table 3. Adjusted Associations of Depression at Baseline With All-Cause and Cardiovascular Disease Mortality Among
Participants With PAD (N=951)
All-Cause Mortality Cardiovascular Disease Mortality
Adjusted Hazard
Ratio (95% CI)
Adjusted Hazard Ratio
With Adjustment for
6-Minute Walk (95% CI)
Adjusted Hazard
Ratio (95% CI)
Adjusted Hazard Ratio
With Adjustment for
6-Minute Walk (95% CI)
Depressed at baseline 1.57 (1.12–2.21) 1.25 (0.87–1.79) 1.80 (1.03–3.13) 1.38 (0.77–2.46)
Age, y 1.04 (1.02–1.06) 1.03 (1.01–1.05) 1.06 (1.03–1.09) 1.05 (1.01–1.08)
Male sex 1.52 (1.12–2.07) 1.73 (1.27–2.37) 1.51 (0.90–2.54) 1.85 (1.08–3.16)
African American race 0.85 (0.58–1.25) 0.79 (0.53–1.17) 0.99 (0.52–1.88) 0.91 (0.48–1.74)
Body mass index, kg/m2 0.96 (0.93–0.99) 0.95 (0.92–0.98) 0.97 (0.92–1.02) 0.95 (0.90–1.01)
Current smoker 1.00 (0.68–1.47) 0.96 (0.65–1.41) 1.35 (0.72–2.55) 1.29 (0.68–2.44)
Diabetes 1.24 (0.91–1.69) 1.17 (0.86–1.60) 1.28 (0.77–2.14) 1.16 (0.69–1.94)
Pulmonary disease 1.20 (0.90–1.62) 1.09 (0.81–1.48) 1.09 (0.66–1.79) 0.97 (0.58–1.62)
Cancer 1.78 (1.28–2.48) 1.73 (1.24–2.42) 0.77 (0.39–1.55) 0.72 (0.36–1.46)
Angina 1.14 (0.82–1.59) 1.11 (0.80–1.55) 1.74 (1.02–2.96) 1.71 (1.00–2.93)
Myocardial infarction 0.91 (0.64–1.29) 0.90 (0.64–1.28) 0.84 (0.47–1.52) 0.84 (0.47–1.51)
Stroke 1.16 (0.80–1.69) 1.02 (0.70–1.49) 1.28 (0.68–2.40) 1.06 (0.55–2.02)
Heart failure 1.63 (1.16–2.29) 1.52 (1.08–2.14) 1.59 (0.91–2.77) 1.39 (0.79–2.45)
Ankle–brachial index 0.58 (0.22–1.51) 0.95 (0.36–2.49) 0.58 (0.12–2.69) 1.05 (0.22–5.00)
Statin use 0.80 (0.59–1.10) 0.82 (0.60–1.12) 0.74 (0.44–1.27) 0.76 (0.44–1.30)
ACE inhibitor use 1.23 (0.90–1.67) 1.25 (0.92–1.71) 1.48 (0.88–2.50) 1.54 (0.92–2.58)
Anti-platelet use 0.83 (0.61–1.14) 0.88 (0.64–1.21) 0.60 (0.36–1.01) 0.63 (0.37–1.07)
Median annual household income ≤$51 249 vs
median annual household income >$51 249
1.18 (0.87–1.60) 1.16 (0.85–1.58) 1.07 (0.64–1.81) 1.04 (0.61–1.76)
Less than high school vs graduate school 1.25 (0.73–2.14) 1.15 (0.67–1.98) 1.28 (0.55–2.98) 1.14 (0.49–2.67)
High school to college vs graduate school 1.20 (0.83–1.74) 1.20 (0.83–1.74) 1.07 (0.58–2.00) 1.04 (0.56–1.95)
Six-minute walk (feet) baseline
(HR calculated at unit=100 feet)
NA 0.91 (0.87–0.95) NA 0.89 (0.83–0.96)
ACE indicates angiotensin-converting enzyme; HR, hazard ratio; NA, not available; PAD, peripheral artery disease.
DOI: 10.1161/JAHA.115.002959 Journal of the American Heart Association 9
Depression in Peripheral Artery Disease McDermott et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
part by poorer walking endurance among PAD patients with
depressive symptoms compared to PAD patients without
depressive symptoms. Poorer walking endurance, measured
by the 6-minute walk, is an indicator of PAD severity and an
indicator of presence and severity of multiple chronic
conditions. The 6-minute walk may represent a final common
pathway for the association of PAD with increased risk of
depressive symptoms and for the association of depressive
symptoms with increased mortality among people with PAD.
However, this observational study cannot delineate causal
pathways for the associations reported here. It is possible
that poorer 6-minute walk performance represents psychomo-
tor retardation associated with depression.
Among people with PAD, cross-sectional studies have
documented a high prevalence of depression and poorer
functional performance among depressed patients with PAD
compared to nondepressed patients with PAD.2,6,35 McDer-
mott et al previously reported that greater numbers of
depressive symptoms, measured by the GDS-S, were associ-
ated with slower walking velocity and poorer 6-minute walk
performance among 423 men and women with PAD even after
adjusting for confounders including the ABI.35 Smolderan
et al previously reported that the prevalence of depression
among 166 patients with PAD was 16%, measured by a Center
for Epidemiological Studies Depression scale score ≥4, and
that PAD patients with depression had poorer treadmill
walking performance compared to PAD patients without
depression.2 In longitudinal analyses, Cherr et al studied
patients with PAD undergoing lower extremity revasculariza-
tion.6,36 The prevalence of depression at baseline was 35%.6
PAD patients undergoing lower extremity revascularization
with depression at baseline had higher rates of failed
revascularization, lower patency rates, and higher rates of
the combined outcome of all-cause mortality and cardiovas-
Table 4. Adjusted Associations of Decline in the ABI During First 2 Years of Follow-Up With Subsequent Rate of Depression
Participants With PAD (N=354) Participants Without PAD (N=262)
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Decline in ABI >0.15 vs decline in ABI ≤0.15* 0.94 (0.31–2.86) 0.913 3.88 (1.09–13.89) 0.037
Age, y 1.02 (0.97–1.06) 0.478 1.00 (0.94–1.07) 0.941
Male sex 0.62 (0.32–1.22) 0.166 1.42 (0.53–3.81) 0.490
African American race 0.60 (0.20–1.79) 0.363 0.66 (0.19–2.36) 0.522
Six-minute walk (feet) baseline (hazard ratio
calculated per 100 feet)
0.97 (0.87–1.09) 0.621 0.85 (0.76–0.97) 0.013
Body mass index, kg/m2 1.07 (1.00–1.15) 0.044 1.05 (0.97–1.13) 0.254
Current smoker 3.08 (1.39–6.80) 0.005 0.00 (0.00–1) 0.993
Diabetes 1.37 (0.68–2.78) 0.381 0.82 (0.21–3.20) 0.771
Pulmonary disease 1.22 (0.59–2.54) 0.589 1.31 (0.51–3.36) 0.580
Cancer 2.51 (1.15–5.49) 0.021 1.25 (0.32–4.89) 0.745
Angina 0.93 (0.42–2.06) 0.861 1.54 (0.39–6.14) 0.542
Myocardial infarction 1.17 (0.53–2.61) 0.694 1.29 (0.26–6.33) 0.750
Stroke 0.61 (0.21–1.77) 0.363 0.00 (0.00–1) 0.994
Heart failure 2.09 (0.96–4.55) 0.062 1.50 (0.34–6.59) 0.590
Hip arthritis 0.80 (0.08–7.66) 0.844 2.48 (0.26–23.31) 0.428
Knee arthritis 1.92 (0.73–5.06) 0.187 2.78 (0.90–8.57) 0.076
Disk disease 0.77 (0.37–1.57) 0.468 0.99 (0.37–2.61) 0.983
Spinal stenosis 0.39 (0.10–1.48) 0.167 1.07 (0.41–2.79) 0.886
ABI 1.22 (0.10–14.98) 0.874 3.29 (0.04–286.09) 0.602
Median annual household income ≤$51 249 vs
median annual household income >$51 249
0.50 (0.25–1.00) 0.049 0.79 (0.29–2.16) 0.641
Less than high school vs graduate school 2.92 (0.81–10.59) 0.102 0.82 (0.15–4.35) 0.814
High school to college vs graduate school 1.80 (0.71–4.56) 0.217 0.30 (0.11–0.79) 0.015
ABI indicates Ankle–Brachial Index; PAD, peripheral artery disease.
*Decline in the ABI during the first 2 years of follow-up was related to subsequent risk of depression.
DOI: 10.1161/JAHA.115.002959 Journal of the American Heart Association 10
Depression in Peripheral Artery Disease McDermott et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
cular disease events during follow-up compared to PAD
patients undergoing revascularization without depression at
baseline.6,37 Depression was also associated with a higher
rate of coronary heart disease events but was not associated
with higher rates of all-cause mortality or cerebrovascular
events, respectively.6 Previous study from the Heart and Soul
study of 1024 men and women with coronary artery disease
demonstrated that the presence of depressive symptoms at
baseline was associated with a higher incidence of PAD during
follow-up in analyses adjusting for age and sex (HR=2.09, 95%
CI=1.09–4.00).34 However, this association was no longer
significant after additional adjustment for comorbidities, PAD
risk factors, medications, and health behaviors.
To our knowledge, no prior studies have compared the
incidence of depression in longitudinal analyses between
people with versus without PAD. To our knowledge, no prior
studies have compared all-cause or cardiovascular disease
mortality rates between PAD patients with versus without
depression, in a cohort of PAD participants not undergoing
revascularization. Our study design does not allow us to
discern potential mechanisms of our findings. However,
previous study suggests that depression is associated with
more adverse health behaviors, such as greater inactivity.37
Prior study also suggests that depression is associated with
adverse pathophysiologic changes that include increased
sympathetic tone, reduced vagal tone, and immunosuppres-
sion.38–40 These pathophysiologic changes may increase risk
of mortality among PAD patients with depression. Further
study is needed to discern the mechanisms of the associa-
tions reported here.
Table 5. Adjusted Associations of Decline in the Six-Minute Walk During First 2 Years of Follow-Up With Subsequent Depression
Among Participants With and Without PAD
Participants With PAD (N=298) Participants Without PAD (N=250)
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Decline in 6-min walk: tertile 3 vs tertile 1* 2.28 (0.96–5.45) 0.063 4.72 (1.09–20.47) 0.038
Decline in 6-min walk: tertile 2 vs tertile 1* 1.16 (0.45–2.97) 0.760 3.14 (0.70–14.06) 0.135
Age, y 1.00 (0.95–1.05) 0.914 0.98 (0.91–1.05) 0.561
Male sex 0.75 (0.35–1.59) 0.448 1.20 (0.44–3.30) 0.717
African American race 0.63 (0.18–2.24) 0.475 0.42 (0.09–2.03) 0.279
Six-minute walk (feet) baseline (hazard ratio
calculated per 100 feet)
0.97 (0.86–1.11) 0.691 0.78 (0.67–0.91) 0.002
Body mass index, kg/m2 1.09 (1.00–1.19) 0.039 1.02 (0.94–1.12) 0.610
Current smoker 3.33 (1.34–8.26) 0.010 0.00 (0.00–1) 0.995
Diabetes 1.39 (0.62–3.10) 0.419 1.32 (0.32–5.46) 0.704
Pulmonary disease 1.11 (0.48–2.55) 0.808 1.65 (0.63–4.32) 0.309
Cancer 1.94 (0.74–5.12) 0.178 1.76 (0.44–7.03) 0.427
Angina 1.04 (0.45–2.41) 0.923 2.19 (0.50–9.56) 0.295
Myocardial infarction 1.33 (0.57–3.12) 0.511 0.87 (0.15–5.02) 0.879
Stroke 1.05 (0.36–3.08) 0.934 0.00 (0.00–1) 0.994
Heart failure 2.22 (0.94–5.21) 0.068 1.57 (0.35–7.15) 0.557
Hip arthritis 0.00 (0.00–1) 0.991 3.48 (0.29–42.11) 0.326
Knee arthritis 1.81 (0.66–4.97) 0.249 2.44 (0.72–8.27) 0.151
Disk disease 0.93 (0.42–2.05) 0.854 0.88 (0.32–2.39) 0.799
Spinal stenosis 0.66 (0.16–2.68) 0.559 0.77 (0.27–2.19) 0.619
Ankle brachial index 0.50 (0.03–9.31) 0.643 9.61 (0.07–1357.64) 0.370
Median annual household income ≤$51 249 vs
median annual household income >$51 249
0.53 (0.25–1.11) 0.094 0.61 (0.21–1.82) 0.380
Less than high school vs graduate school 1.51 (0.33–6.97) 0.601 0.78 (0.13–4.53) 0.781
High school to college vs graduate school 1.42 (0.52–3.91) 0.498 0.38 (0.13–1.09) 0.072
PAD indicates peripheral artery disease.
*Tertile 1 represents the best (least) decline in the 6-minute walk between baseline and 2-year follow-up. Analyses relate change in 6-minute walk during the first 2 years of follow-up with
subsequent incidence of depression.
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Our study has limitations. First, our data are observa-
tional. Results cannot be construed as causal. Second,
although our findings suggest that the 6-minute walk may
mediate the associations reported here, these observational
data prevent the ability to delineate the causal pathway of
findings reported here. Third, we used the GDS-S to
measure depression. We did not collect data on clinical
diagnoses of depression. However, previous study demon-
strates that the GDS-S is a well-validated measure of
depression.13–18 Fourth, we excluded PAD participants who
were wheelchair bound and those residing in a nursing
home, who may have had a higher prevalence of depression
than the participants included here. Our results may not be
generalizable to people who did not meet our inclusion
criteria. Fifth, our analyses combined data from 3 observa-
tional prospective cohorts of participants with PAD, thereby
introducing heterogeneity into our analyses. We addressed
heterogeneity by stratifying our analyses by study cohort
and by testing for a cohort interaction for our primary
analyses. Sixth, participants were identified from among
patients encountered by physicians in multiple office
settings in Chicago. Our findings may not be generalizable
to men and women not encountered by clinicians in an
office or medical center setting. Seventh, although the GDS-
S is well validated in multiple settings, to our knowledge, it
has not been validated against a clinical diagnosis of
depression specifically in a population of patients with
established cardiovascular disease.
In conclusion, people with PAD are at higher risk for
developing depression compared to people without PAD.
Among people with PAD, depression is associated with higher
mortality rates compared to the absence of depression. Our
findings suggest that clinicians should be alert to an increased
incidence of depression among people with PAD. Clinicians
should also be aware that the presence of depression in
people with PAD is associated with increased mortality.
Further study is needed to determine whether improving 6-
minute walk performance can prevent depression in PAD and
whether treating depression can reduce all-cause and cardio-
vascular disease mortality in people with PAD. Further study is
also needed to delineate the mechanisms of associations
reported here.
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